Marker Therapeutics, Inc. — Director's Dealing 2016

Aug 25, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-08-25

Reporting Person: Loiacono Michael (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-25	Employee Stock Option (Right to Buy)	$0.475	A	650000	Acquired	2026-08-25	Common Stock (650000)	Direct

Footnotes

F1: Represents options awarded under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of Mr. Loiacono's employment agreement with the Company. 75,008 options shall vest immediately and the remaining options shall vest in 36 equal monthly installments of 15,972 options on the last day of each of the 36 months following the grant date. The option exercise price is the closing price on August 24, 2016 the trading day immediately prior to the award date.